Efficacy and safety of once-weekly semaglutide vs sitagliptin as add-on to metformin and/or thiazolidinediones after 56 weeks in subjects with type 2 diabetes (SUSTAIN 2)

被引：0
|
作者：
Ahren, B. [1 ]
Comas, L. Masmiquel [2 ]
Kumar, H. [3 ]
Sargin, M. [4 ]
Karsbol, J. Derving [5 ]
Jacobsen, S. Hald [5 ]
Chow, F. [6 ]
机构：
[1] Lund Univ, Lund, Sweden
[2] Hosp Quiron Palmaplanas, Palma De Mallorca, Spain
[3] Amrita Inst Med Sci & Res Ctr, Kochi, India
[4] Kartal Lufti Kirdar Training & Res Hosp, Istanbul, Turkey
[5] Novo Nordisk AS, Soborg, Denmark
[6] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China
来源：
DIABETOLOGIA | 2016年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
767
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of tirzepatide versus semaglutide once weekly as add-on therapy to metformin in people with type 2 diabetes (SURPASS-2)
    Davies, M. J.
    Frias, J. P.
    Rosenstock, J.
    Perez Manghi, F.
    Lando, L. Fernandez
    Bergman, B. K.
    Liu, B.
    Cui, X.
    Brown, K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 14 - 15
  • [22] Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial
    Ji, Linong
    Dong, Xiaolin
    Li, Yiming
    Li, Yufeng
    Lim, Soo
    Liu, Ming
    Ning, Zu
    Rasmussen, Soren
    Skjoth, Trine Vang
    Yuan, Guoyue
    Eliaschewitz, Freddy G.
    DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 404 - 414
  • [23] Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
    Capehorn, M. S.
    Catarig, A-M
    Furberg, J. K.
    Janez, A.
    Price, H. C.
    Tadayon, S.
    Verges, B.
    Marre, M.
    DIABETES & METABOLISM, 2020, 46 (02) : 100 - 109
  • [24] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [25] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    DIABETES, 2021, 70
  • [26] Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
    Seino, Yutaka
    Terauchi, Yasuo
    Osono, Takeshi
    Yabe, Daisuke
    Abe, Nobuyuki
    Nishida, Tomoyuki
    Zacho, Jeppe
    Kaneko, Shizuka
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 378 - 388
  • [27] Efficacy and safety of once-weekly semaglutide in elderly subjects with type 2 diabetes: post hoc analysis of SUSTAIN 1-5 trials
    Warren, M.
    Chaykin, L.
    Trachtenbarg, D.
    Nayak, G.
    Wijayasinghe, N.
    Cariou, B.
    DIABETOLOGIA, 2017, 60 : S378 - S379
  • [28] Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naive subjects with type 2 diabetes (SUSTAIN 4)
    Aroda, Vanita
    Bain, Stephen
    Cariou, Bertrand
    Piletic, Milivoj
    Rose, Ludger
    Bergan, Eirik Quamme
    Zacho, Jeppe
    Devries, J. Hans
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S51 - S51
  • [29] Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
    Lingvay, Ildiko
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Kumar, Harish
    Lausvig, Nanna L.
    le Roux, Caret W.
    Thielke, Desiree
    Viljoen, Adie
    McCrimmon, Rory J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 834 - 844
  • [30] Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Persson, Sofie
    Grip, Emilie Toresson
    DIABETES, 2018, 67
12345